Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab

This study will include a retrospective and prospective observational database analysis.

Inclusion Criteria:

- Age greater than or equal to18 years;

- First allogeneic HCT for cHL;

- Patients with prior autologous HCT for cHL;

- Any conditioning regimen, graft source or donor type.

- For the primary analysis additional criterion includes prior exposure to nivolumab for
treatment of cHL immediately prior to the allogeneic HCT, as defined as nivolumab used
alone or in combination with other agents and used as the last line of therapy prior
to an allogeneic HCT with the interval between the last dose of nivolumab and start of
the conditioning regimen no longer than 12 months.

Exclusion Criteria:

- Patients with nodular lymphocyte-predominant HL

- Previous chimeric antigen receptor T-cell therapy or other genetically modified
cellular product